EXHIBIT 99.1
(ATS MEDICAL LOGO)
CONTACTS:
Michael Dale, President/CEO Investors:
763-553-7736 Jennifer Beugelmans, 646-201-5447
Michael Kramer, Senior Director of Finance Doug Sherk, 415-896-6820
763-557-2222 Steve DiMattia, 646-201-5445 (Media)
ATS MEDICAL PROVIDES PRELIMINARY REVENUE OUTLOOK FOR
FOURTH QUARTER AND FULL YEAR 2006
Full Year Revenue Expected to Exceed Guidance of $40 Million
MINNEAPOLIS, January 25, 2007 -- ATS Medical, Inc. (NASDAQ: ATSI) manufacturer
and marketer of state-of-the-art cardiac surgery products and services, today
released preliminary revenue results for the fourth quarter and full year ended
December 31, 2006.
Total fourth quarter revenue is expected to be approximately $10.6 to $10.8
million compared with $9.9 million in the fourth quarter of 2005. For 2006, ATS
Medical expects to report revenue of approximately $40.3 to $40.5 million.
Michael Dale, President and CEO said, "When we began the year, our goal was to
achieve $40 million in revenue and we are pleased to have surpassed this metric.
We believe that the continued successful execution of our diversification
strategy will enable us to generate further revenue growth in 2007."
ATS Medical plans to issue final results for the fourth quarter and full year
2006 and conduct a conference call after market close during the week of March
5, 2007. At that time the Company will also provide an update on the clinical
and regulatory progress of its ATS 3f(R) tissue heart valve products and PARSUS
blood filtration development project.
ABOUT ATS MEDICAL
ATS Medical, Inc. provides innovative products and services focused on cardiac
surgery. The company, global in scope, has been headquartered in Minneapolis,
Minnesota since its founding in 1991. More than 130,000 ATS Open Pivot(R) Heart
Valves, which utilize a unique pivot design resulting in exceptional performance
and low risk profile, have been implanted in patients worldwide. The ATS 3F(R)
brand encompasses multiple tissue heart valve product offerings at varying steps
from market introductions to clinical trials to development projects that
incorporate less invasive valve replacement technology. ATS Medical's focus on
cardiac surgery is further strengthened by offerings that include ATS
Simulus(TM) annuloplasty products for heart valve repair, SurgiFrost(R) and
FrostByte(TM) products for surgical cryoablation of cardiac arrhythmias,
RTI-Cardiovascular for allograft tissue services, and the development of PARSUS
blood filtration technology. The ATS Medical web site is
http://www.atsmedical.com.
SAFE HARBOR
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company and
its management. Actual results could differ materially from those projected in
the forward looking statements as a result of a number of important factors,
including the results of clinical trials, the integration of 3F Therapeutics,
regulatory actions, competition, pricing pressures, supplier actions and
management of growth. For a discussion of these and other risks and
uncertainties that could affect the
Company's activities and results, please refer to the Company's filings with the
Securities and Exchange Commission including its Form 10-K for the year ended
December 31, 2005, as amended, and its Form S-4 Registration Statement, as
amended, filed with respect to the merger with 3F Therapeutics.
###